Cannabinoids control spasticity and tremor in a multiple sclerosis model D Baker, G Pryce, JL Croxford, P Brown, RG Pertwee, JW Huffman, ... Nature 404 (6773), 84-87, 2000 | 807 | 2000 |
Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain L Cristino, L De Petrocellis, G Pryce, D Baker, V Guglielmotti, V Di Marzo Neuroscience 139 (4), 1405-1415, 2006 | 562 | 2006 |
The therapeutic potential of cannabis D Baker, G Pryce, G Giovannoni, AJ Thompson The Lancet Neurology 2 (5), 291-298, 2003 | 554 | 2003 |
Endocannabinoids control spasticity in a multiple sclerosis model D Baker, G Pryce, JL Croxford, P Brown, RG Pertwee, A Makriyannis, ... The FASEB journal 15 (2), 300-302, 2001 | 495 | 2001 |
In silico patent searching reveals a new cannabinoid receptor D Baker, G Pryce, WL Davies, CR Hiley Trends in pharmacological sciences 27 (1), 1-4, 2006 | 447 | 2006 |
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells K Maresz, G Pryce, ED Ponomarev, G Marsicano, JL Croxford, LP Shriver, ... Nature medicine 13 (4), 492-497, 2007 | 433 | 2007 |
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis G Pryce, Z Ahmed, DJR Hankey, SJ Jackson, JL Croxford, JM Pocock, ... Brain 126 (10), 2191-2202, 2003 | 430 | 2003 |
Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis J Greenwood, CE Walters, G Pryce, N Kanuga, E Beraud, D Baker, ... FASEB journal: official publication of the Federation of American Societies …, 2003 | 295 | 2003 |
MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. MA Lopez-Ramirez, D Wu, G Pryce, JE Simpson, A Reijerkerk, ... FASEB journal 28 (6), 2551-2565, 2014 | 271 | 2014 |
Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis D Baker, M Marta, G Pryce, G Giovannoni, K Schmierer EBioMedicine 16, 41-50, 2017 | 269 | 2017 |
Pharmacological foundations of cannabis chemovars MA Lewis, EB Russo, KM Smith Planta medica 84 (04), 225-233, 2018 | 211 | 2018 |
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases D Baker, CAK Roberts, G Pryce, AS Kang, M Marta, S Reyes, K Schmierer, ... Clinical & Experimental Immunology 202 (2), 149-161, 2020 | 206 | 2020 |
SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics J Greenwood, G Pryce, L Devine, DK Male, WLC dos Santos, VL Calder, ... Journal of neuroimmunology 71 (1-2), 51-63, 1996 | 187 | 1996 |
Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice. LG Bilsland, JRT Dick, G Pryce, S Petrosino, V Di Marzo, D Baker, ... FASEB journal 20 (7), 2006 | 176 | 2006 |
Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors G Pryce, D Baker British journal of pharmacology 150 (4), 519-525, 2007 | 156 | 2007 |
Lymphocyte migration into brain modelled in vitro: control by lymphocyte activation, cytokines, and antigen D Male, G Pryce, C Hughes, P Lantos Cellular immunology 127 (1), 1-11, 1990 | 152 | 1990 |
Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis JM Anderson, DW Hampton, R Patani, G Pryce, RA Crowther, R Reynolds, ... Brain 131 (7), 1736-1748, 2008 | 150 | 2008 |
Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an … CE Walters, G Pryce, DJR Hankey, SM Sebti, AD Hamilton, D Baker, ... The Journal of Immunology 168 (8), 4087-4094, 2002 | 147 | 2002 |
Antigen presentation in brain: MHC induction on brain endothelium and astrocytes compared. DK Male, G Pryce, CC Hughes Immunology 60 (3), 453, 1987 | 138 | 1987 |
Medicinal cannabis: is Δ9–tetrahydrocannabinol necessary for all its effects? JD Wilkinson, BJ Whalley, D Baker, G Pryce, A Constanti, S Gibbons, ... Journal of Pharmacy and Pharmacology 55 (12), 1687-1694, 2003 | 119 | 2003 |